Site Metrics and Web Analytics by WebSTAT
Home > Catalog > Learning - Memory - Attention - Addiction
Product
Category
PACKWIN
(Model: PACKWIN)
Powerful tool for developing a wide range of experiments
in different types of behaviour chambers
User-friendly and versatile Software platform


- More information - - Documents - - Contact Bioseb -
Publications
Technical specifications
Other products / accessory  
Download PDF
This page is available in following languages:
! NEW RESEARCH WORK ! A recent publication by J Jeanblanc, E Bourguet, D Sketriené, C Gonzalez, G Moroy, R Legastelois, M Létévé, A Trussardi-Régnier, M Naassila in "Psychopharmacology" highlights the merits of using Bioseb's Packwin: Interest of new alkylsulfonylhydrazide-type compound in the treatment of alcohol use disorders

Interest of new alkylsulfonylhydrazide-type compound in the treatment of alcohol use disorders
J Jeanblanc, E Bourguet, D Sketriené, C Gonzalez, G Moroy, R Legastelois, M Létévé, A Trussardi-Régnier, M Naassila
Groupe de Recherche sur l’Alcool et les Pharmacodépendances, Université de Picardie Jules Verne, Amiens, France
Published in "Psychopharmacology" (2018-04-30)


Rationale: Recent preclinical research suggested that histone deacetylase inhibitors (HDACIs) and specifically class I HDAC selective inhibitors might be useful to treat alcohol use disorders (AUDs).
Objective: The objective of this study was to find a new inhibitor of the HDAC-1 isoenzyme and to test its efficacy in an animal model of AUDs.
Methods: In the present study, we prepared new derivatives bearing sulfonylhydrazide-type zinc-binding group (ZBG) and evaluated these compounds in vitro on HDAC-1 isoenzyme. The most promising compound was tested on ethanol operant self-administration and relapse in rats.
Results: We showed that the alkylsulfonylhydrazide-type compound (ASH) reduced by more than 55% the total amount of ethanol consumed after one intracerebroventricular microinjection, while no effect was observed on motivation of the animals to consume ethanol. In addition, one ASH injection in the central amygdala reduced relapse.
Conclusions: Our study demonstrated that a new compound designed to target HDAC-1 is effective in reducing ethanol intake and relapse in rats and further confirm the interest of pursuing research to study the exact mechanism by which such inhibitor may be useful to treat AUDs.

Presentation

PACKWIN is a user-friendly and versatile Software platform developed with the aim to offer a powerful tool for conducting a wide range of experiments in different types of behaviour chambers. It typically controls the BIOSEB standard chambers for operant conditioning, self-administration, 5/9 hole and Vogel test, but its range of compatibility allows working with other behavioural chambers for Active/Passive avoidance and fear conditioning experiments...


Operating principle

Due to his new modular structure, PACKWIN 2.0. can be used in a highly flexible structure (Customised module – CS) allowing the experimenter to build a wide variety of different protocols for the configuration of basic programs for operant procedure (fixed and variable ratio, fixed or variable interval, fixed or variable DRL, positive and negative reinforcement, extinction, probability to obtain a reinforcement, etc.) with or without discriminative stimuli (light, sound) as well as more specific and complex user-defined protocols (conflict, DMTS, 5 choice serial reaction task etc.). Give the PACKWIN state-editor tool the opportunity to surprise yourself by its straightforwardness (no need of specific programming skills)!! A great number of editable raw data table and outpout numeric data&graph reports are provided integrated in the all-in-one structure of the software.

PACKWIN 2.0. also offers new specific experimental modules providing convenient protocol editor templates and ready-to-use run panels and data reports directly targeted to specific standard experiments such as the 5-choice Serial Reaction Time Task (5/9 hole module – HO) and the Vogel test.

In PACKWIN 2.0 version, a step ahead has been made in terms of user-interface and features that no other software available in the market can offer right now: new aperture assistant and experimental tool bar for guiding the user along the experimental process, new chamber simulator for checking your protocols without interrupting the data acquired from the real chambers, new batch analysis features for increasing the productivity of your experiment, integrated numerical and graph reports, direct exportation to Excel... and many other essential functions!


Parameters Measured

• Customized Summary report (experiment duration, response related data: number, latencies, duration, rate, Inter-Response time, ...)
• Response by time report (number of response by user-defined intervals of time)
• Response pattern report by group (pattern plot of response distribution along the time)
• Single-sessions reports (Events history, Acquisition Replay, Cumulated curve and Response pattern plots)


State editor tool
State editor tool
Domains of application

• ANXIETY
- The most prevalent of the psychiatric diseases
- Anxiety disorders

• ATTENTION
- Divided attention
- Selective attention
- Attention-deficit / hyperactivity disorder (ADHD), the most commonly psychiatric disorder of childhood
- Schizophrenia
- Autism
- Age-related decline of memory performances

• DEPRESSION
- Normal, transient unhappiness
- Pathological states of hopelessness

• LEARNING AND MEMORY
- Learning disabilities associated with aging
- Alzheimer’s disease and brain damages
- Huntington's disease
- Multiple sclerosis
- Parkinson's disease
- HIV
- Studies about learning and memory neurobiological mechanisms
- Learning and memory abilities in response to drugs administration

• REWARD AND ADDICTION
- Compulsive behavior which is reinforced or rewarded
- Drug addiction
- Chronic drug abuse


Key features

Even more user-friendly interface!
• Aperture assistant and experimental tool bar
• Modular structure (targeted to specific experiments or fully customizable)
• Straigthforward “State-Editor” tool for protocol configurations (no need of specific programming skills)
• Assistant panels and specific reports for 5/9 holes procedures and Vogel test
• Operant chamber simulator tool (unique feature in the market!)
• Test boxes function for hardware checking purpose
• Built-in Yoked procedure settings
• Optimal data traceability
• Integrated potent analysis module and plot makers
• Batch analysis and direct exportation to Excel (1 session per row)


Options
• Tailor-made Experimental Configuration Setups upon request


Publications (Click on an article to show details and read the abstract)

MOOD DISORDERS
- Anxiety -
Gpr158 mediates osteocalcinÕs regulation of cognition (2017)
Gpr158 mediates osteocalcinÕs regulation of cognition
L Khrimian, A Obri, M Ramos-Brossier, A Rousseaud, S Moriceau, A-S Nicot, P Mera, S Kosmidis, T Karnavas, F Ssudou, X-B Gao, F Oury, E Kandel, G Karsenty
Department of Genetics and Development, Columbia University Medical Center, New York, NY
Published in "Journal of Experimental Medicine" (2017-08-29)

That osteocalcin (OCN) is necessary for hippocampal-dependent memory and to prevent anxiety-like behaviors raises novel questions. One question is to determine whether OCN is also sufficient to improve these behaviors in wild-type mice, when circulating levels of OCN decline as they do with age. Here we show that the presence of OCN is necessary for the beneficial influence of plasma from young mice when injected into older mice on memory and that peripheral delivery of OCN is sufficient to improve memory and decrease anxiety-like behaviors in 16-mo-old mice. A second question is to identify a receptor transducing OCN signal in neurons. Genetic, electrophysiological, molecular, and behavioral assays identify Gpr158, an orphan G proteinÐcoupled receptor expressed in neurons of the CA3 region of the hippocampus, as transducing OCNÕs regulation of hippocampal-dependent memory in part through inositol 1,4,5-trisphosphate and brain-derived neurotrophic factor. These results indicate that exogenous OCN can improve hippocampal-dependent memory in mice and identify molecular tools to harness this pathway for therapeutic purposes.

OTHER DISORDERS
- Cognitive performance -
Gpr158 mediates osteocalcinÕs regulation of cognition (2017)
Gpr158 mediates osteocalcinÕs regulation of cognition
L Khrimian, A Obri, M Ramos-Brossier, A Rousseaud, S Moriceau, A-S Nicot, P Mera, S Kosmidis, T Karnavas, F Ssudou, X-B Gao, F Oury, E Kandel, G Karsenty
Department of Genetics and Development, Columbia University Medical Center, New York, NY
Published in "Journal of Experimental Medicine" (2017-08-29)

That osteocalcin (OCN) is necessary for hippocampal-dependent memory and to prevent anxiety-like behaviors raises novel questions. One question is to determine whether OCN is also sufficient to improve these behaviors in wild-type mice, when circulating levels of OCN decline as they do with age. Here we show that the presence of OCN is necessary for the beneficial influence of plasma from young mice when injected into older mice on memory and that peripheral delivery of OCN is sufficient to improve memory and decrease anxiety-like behaviors in 16-mo-old mice. A second question is to identify a receptor transducing OCN signal in neurons. Genetic, electrophysiological, molecular, and behavioral assays identify Gpr158, an orphan G proteinÐcoupled receptor expressed in neurons of the CA3 region of the hippocampus, as transducing OCNÕs regulation of hippocampal-dependent memory in part through inositol 1,4,5-trisphosphate and brain-derived neurotrophic factor. These results indicate that exogenous OCN can improve hippocampal-dependent memory in mice and identify molecular tools to harness this pathway for therapeutic purposes.

- Addiction -
Interest of new alkylsulfonylhydrazide-type compound in the treatment of alcohol use disorders (2018)
Interest of new alkylsulfonylhydrazide-type compound in the treatment of alcohol use disorders
J Jeanblanc, E Bourguet, D Sketriené, C Gonzalez, G Moroy, R Legastelois, M Létévé, A Trussardi-Régnier, M Naassila
Groupe de Recherche sur l’Alcool et les Pharmacodépendances, Université de Picardie Jules Verne, Amiens, France
Published in "Psychopharmacology" (2018-04-30)

Rationale: Recent preclinical research suggested that histone deacetylase inhibitors (HDACIs) and specifically class I HDAC selective inhibitors might be useful to treat alcohol use disorders (AUDs).
Objective: The objective of this study was to find a new inhibitor of the HDAC-1 isoenzyme and to test its efficacy in an animal model of AUDs.
Methods: In the present study, we prepared new derivatives bearing sulfonylhydrazide-type zinc-binding group (ZBG) and evaluated these compounds in vitro on HDAC-1 isoenzyme. The most promising compound was tested on ethanol operant self-administration and relapse in rats.
Results: We showed that the alkylsulfonylhydrazide-type compound (ASH) reduced by more than 55% the total amount of ethanol consumed after one intracerebroventricular microinjection, while no effect was observed on motivation of the animals to consume ethanol. In addition, one ASH injection in the central amygdala reduced relapse.
Conclusions: Our study demonstrated that a new compound designed to target HDAC-1 is effective in reducing ethanol intake and relapse in rats and further confirm the interest of pursuing research to study the exact mechanism by which such inhibitor may be useful to treat AUDs.


THE INFORMATION IN THIS WEB SITE AND IN LINKED PAGES AND DOCUMENTS IS PROVIDED "AS IS" AND DOES NOT CREATE ANY EXPRESS OR IMPLIED WARRANTY ABOUT BIOSEB OR ITS PRODUCTS OR SERVICES.

Information published on this Web Site as well as services, product specifications, availability and prices are subject to change without notice. BIOSEB may also make improvements and/or changes in the products and/or the programs described in this Web Site at any time without notice.

BIOSEB has made reasonable efforts to verify that the information in this Web site was accurate when first published. Such information may contain errors or omissions, however, and it is subject to change without notice. Bioseb does not undertake to update this information to include any such changes or to correct errors or omissions. Bioseb assumes no responsibility for any use of the information in this Web site or for any infringement of patents or other rights of third parties that may result. Certain information may be country-specific and may not apply in all countries.

Computer requirements 2,2 GHz processor or higher (Celeron processor not supported), 2 Gb of RAM, HD250 Gb (150 MB free hard disk space), 1024X768 pixels and 32-bit true colour Graphics, 2 USB free ports.
System requirements Windows 7 (32 bits) compatible operating system
Connection of several units
to PC
One cable connects all units to the PC through RS-232/USB port
(no PCI card needed)

Model:
PACKWIN
Packwin
Contact us

Related products:
LE507
5-9 holes attention processes box
for mouse Contact us
LE862
Vogel's test
for mice and rats < 350 g Contact us
Print version

Bioseb - In Vivo Research Instruments
Phone worldwide : +33 442 344 360 - USA/Canada : (727) 521-1808
e-Mail : Worldwide: info@bioseb.com - USA/Canada: info-us@bioseb.com